Influence of tumor-infiltrating immune cells on local control rate, distant metastasis, and survival in patients with soft tissue sarcoma.
Soft tissue sarcoma
immune cell profile
macrophages
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
11 03 2021
11 03 2021
Historique:
entrez:
25
3
2021
pubmed:
26
3
2021
medline:
3
8
2021
Statut:
epublish
Résumé
Soft tissue sarcomas (STS) are considered non-immunogenic, although distinct entities respond to anti-tumor agents targeting the tumor microenvironment. This study's aims were to investigate relationships between tumor-infiltrating immune cells and patient/tumor-related factors, and assess their prognostic value for local recurrence (LR), distant metastasis (DM), and overall survival (OS). One-hundred-eighty-eight STS-patients (87 females [46.3%]; median age: 62.5 years) were retrospectively analyzed. Tissue microarrays (in total 1266 cores) were stained with multiplex immunohistochemistry and analyzed with multispectral imaging. Seven cell types were differentiated depending on marker profiles (CD3+, CD3+ CD4+ helper, CD3+ CD8+ cytotoxic, CD3+ CD4+ CD45RO+ helper memory, CD3+ CD8+ CD45RO+ cytotoxic memory T-cells; CD20 + B-cells; CD68+ macrophages). Correlations between phenotype abundance and variables were analyzed. Uni- and multivariate Fine&Gray and Cox-regression models were constructed to investigate prognostic variables. Model calibration was assessed with C-index. IHC-findings were validated with TCGA-SARC gene expression data of genes specific for macrophages, T- and B-cells. B-cell percentage was lower in patients older than 62.5 years (
Identifiants
pubmed: 33763294
doi: 10.1080/2162402X.2021.1896658
pii: 1896658
pmc: PMC7954425
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1896658Informations de copyright
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the authors.
Références
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
Cancer Immunol Immunother. 2019 Jun;68(6):927-936
pubmed: 30879106
Clin Cancer Res. 2018 Dec 15;24(24):6125-6135
pubmed: 30049748
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Cancer Cell. 2013 Feb 11;23(2):249-62
pubmed: 23410977
BMC Cancer. 2015 Oct 24;15:790
pubmed: 26497197
Hum Pathol. 1992 Dec;23(12):1410-8
pubmed: 1334945
Oncoimmunology. 2017 Oct 26;7(2):e1386828
pubmed: 29308311
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
PLoS One. 2011 Jan 27;6(1):e14611
pubmed: 21298041
J Immunother Cancer. 2020 May;8(1):
pubmed: 32414858
Cancer Genet. 2019 Jun;235-236:1-12
pubmed: 31296308
Br J Cancer. 2014 Aug 12;111(4):646-50
pubmed: 24755886
Lancet Oncol. 2017 Nov;18(11):1493-1501
pubmed: 28988646
J Transl Med. 2019 Apr 18;17(1):130
pubmed: 30999901
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Arch Immunol Ther Exp (Warsz). 2017 Oct;65(5):445-454
pubmed: 28343267
J Exp Med. 2015 Apr 6;212(4):435-45
pubmed: 25753580
Blood. 1993 Mar 15;81(6):1607-13
pubmed: 7680921
Lancet Oncol. 2018 Mar;19(3):416-426
pubmed: 29370992
J Clin Oncol. 2001 Mar 1;19(5):1248-55
pubmed: 11230465
Ann Surg. 1891 Sep;14(3):199-220
pubmed: 17859590
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Eur J Cancer. 2017 Sep;83:313-323
pubmed: 28797949
Lancet Oncol. 2016 May;17(5):671-80
pubmed: 27068860
Mod Pathol. 2019 Dec;32(12):1772-1785
pubmed: 31263176
J Clin Oncol. 2002 Feb 1;20(3):791-6
pubmed: 11821462
Clin Cancer Res. 2008 Mar 1;14(5):1423-30
pubmed: 18316565
Cancer. 2017 Sep 1;123(17):3291-3304
pubmed: 28463396
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Curr Treat Options Oncol. 2019 Jan 24;20(1):6
pubmed: 30675651
Oncoimmunology. 2017 Nov 20;7(3):e1389366
pubmed: 29399389
FEBS Lett. 2009 Dec 17;583(24):3966-73
pubmed: 19850042
Surg Oncol. 2018 Dec;27(4):695-701
pubmed: 30449495
Sci Rep. 2015 Jun 08;5:10775
pubmed: 26053859
Cancer. 2002 May 1;94(9):2511-6
pubmed: 12015777
Nat Rev Genet. 2012 Mar 13;13(4):227-32
pubmed: 22411467
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv51-iv67
pubmed: 29846498
Mol Biosyst. 2009 Dec;5(12):1512-26
pubmed: 20023718
J Clin Oncol. 2001 Mar 1;19(5):1256-65
pubmed: 11230466
Oncoimmunology. 2020 Apr 12;9(1):1747340
pubmed: 32313727
Nat Rev Immunol. 2012 Feb 17;12(3):191-200
pubmed: 22343568
Oncoimmunology. 2012 Jan 1;1(1):75-77
pubmed: 22720216
Mar Drugs. 2014 Jan 27;12(2):719-33
pubmed: 24473171
Stat Med. 1984 Apr-Jun;3(2):143-52
pubmed: 6463451
Histopathology. 2013 Sep;63(3):309-15
pubmed: 23802739
Med Mol Morphol. 2019 Mar;52(1):44-51
pubmed: 29980952